Colgate-Palmolive Company (CL) is currently trading at $91.63. Based on 20 Wall Street analysts, the average target price is $97.65, implying a 6.6% upside. The consensus recommendation is BUY.

CL

Colgate-Palmolive Company

Consumer StaplesOpinion: buy

Opinion Criteria: Based on the consensus of Wall Street analysts. Strong Buy (1.0-1.5), Buy (1.5-2.5), Hold (2.5-3.5), Sell (3.5-4.5), Strong Sell (4.5-5.0).

Price (USD)

$91.63

Consensus target price range

Low–high band from analyst PT changes in the last 3 months; median & sample mean vs current price

LowHigh
$80.00$110.00
Current $91.63
Median: $96.00Mean: $97.45Current: $91.63

Recent price target updates (latest 80)

  • BarclaysJul 21, 2026

    PT action: Raises

    $80.00 → $87.00

  • JP MorganJul 16, 2026

    PT action: Raises

    $96.00 → $104.00

  • UBSJul 16, 2026

    PT action: Raises

    $100.00 → $106.00

  • CitigroupJul 14, 2026

    PT action: Raises

    $105.00 → $110.00

  • Piper SandlerJul 9, 2026

    PT action: Raises

    $92.00 → $96.00

  • Wells FargoJul 8, 2026

    PT action: Raises

    $92.00 → $95.00

  • BernsteinJun 11, 2026

    PT action: Announces

    $0.00 → $96.00

  • BarclaysMay 5, 2026

    PT action: Raises

    $79.00 → $80.00

  • JP MorganMay 4, 2026

    PT action: Raises

    $95.00 → $96.00

  • UBSMay 4, 2026

    PT action: Raises

    $98.00 → $100.00

  • RBC CapitalMay 4, 2026

    PT action: Maintains

    $102.00 → $102.00

  • Morgan StanleyApr 23, 2026

    PT action: Lowers

    $100.00 → $95.00

  • Rothschild & CoApr 21, 2026

    PT action: Raises

    $93.00 → $100.00

  • JP MorganApr 17, 2026

    PT action: Lowers

    $97.00 → $95.00

  • BarclaysApr 14, 2026

    PT action: Lowers

    $88.00 → $79.00

  • B of A SecuritiesApr 10, 2026

    PT action: Lowers

    $105.00 → $102.00

  • Wells FargoApr 8, 2026

    PT action: Lowers

    $100.00 → $92.00

  • Piper SandlerApr 8, 2026

    PT action: Lowers

    $96.00 → $92.00

  • UBSApr 7, 2026

    PT action: Lowers

    $100.00 → $98.00

  • Deutsche BankMar 30, 2026

    PT action: Raises

    $90.00 → $98.00

Band uses only the revised target (Current column) from firm actions dated within the last 3 months—not the Prior price.

Avg Target

$97.65

Based on 20 analysts

Analyst Recommendations

Buy (13)Hold (7)Sell (1)

Upside

+6.57%

Market Cap

$0.00B

Financial & Investment Metrics

P/E Ratio (TTM)35.52
Forward P/E22.61
P/B Ratio506.24
Dividend Yield2.34%
Return on Equity (ROE)363.58%
Operating Margin20.92%
Debt to Equity1640.54
Beta (Volatility)0.32
52 Week Range$74.55 - $99.33
LowCurrent: $91.63High

Latest News

Daily editorial mentioning CL

Price target moves

Utility Sector Dominates PT Upgrades as IBM Faces $80 Target Slash

The most significant price target shift in our data as of July 17, 2026, involves a sharp $80 reduction for IBM by Argus Research, moving the target from $360 down to $280. While that headline figure captures attention, the broader story over the last 14 days is a concentrated wave of optimism directed at the Utilities sector.

The week in PT changes

JP Morgan led a flurry of activity yesterday, specifically targeting a wide basket of utilities. XEL saw its target climb from $91 to $102, while DUK and ETR received meaningful bumps to $141 and $139, respectively. This movement suggests a coordinated reassessment of defensive, rate-sensitive equities. Elsewhere, Goldman Sachs GS saw its target lifted by Citigroup, moving from $1100 to $1200, even as the analyst noted the stock is currently trading near that ceiling.

The activity was not exclusively bullish. Healthcare names faced notable headwinds, with Truist Securities cutting their outlook on ISRG by $70, taking it from $580 to $510. Similarly, the Consumer Staples space showed mixed sentiment; while JP Morgan pushed CL up to $104, they simultaneously lowered their target on HSY to $190.

Ticker Firm Dir Prior→Current
IBM Argus Down 360→280
ISRG Truist Down 580→510
XEL JP Morgan Up 91→102
GS Citigroup Up 1100→1200

For a full breakdown of the latest volatility across these firms, you can review our moves page to see how these specific revisions align with broader sector trends.

What the data does not say

A price target revision is fundamentally a snapshot of a firm’s internal model, not a reflection of shifting market liquidity or macroeconomic shifts. For instance, the $70 reduction in the ISRG target by Truist is a significant recalibration, yet it sits alongside a 36.6% implied upside, highlighting the gap that often exists between analyst pessimism and the broader consensus mean.

Furthermore, the simultaneous upgrade and downgrade of CAG by different firms on the same day underscores that there is no singular institutional view on consumer staples. Analysts are currently grappling with margin pressures that are not uniformly affecting all companies in the sector. These revisions represent the professional opinion of individual desks, which may intentionally diverge from the consensus to capture a specific thesis regarding interest rates or supply chain costs that the broader market has yet to fully price in.

Read article

Insider Sentiment Index (Last 6 Months)

Counts and listings exclude stock awards, gifts, and option exercises—open-market purchases and sales only.

Buy vs Sell (Count)

Insider Buys: 0Insider Sells: 10

Whale Trades (C-Level Large Buys)

No major insider buying detected recently.

Recent Insider Transactions

DateNamePositionTransactionShares
5/15/2026MALCOLM GREGORYOfficerSale at price 88.44 per share.2,300
5/7/2026MASSEY SALLYOfficerSale at price 87.41 per share.8,599
2/12/2026TSOURAPAS PANAGIOTISOfficerSale at price 94.61 - 97.81 per share.50,000
2/10/2026HAZLIN JOHNOfficerSale at price 94.25 per share.20,989
2/6/2026MALCOLM GREGORYOfficerSale at price 94.91 per share.12,747
2/5/2026MASSEY SALLYOfficerSale at price 95.03 per share.15,851
2/4/2026SUTULA STANLEY J IIIChief Financial OfficerSale at price 94.27 per share.97,843
2/4/2026WALLACE NOEL RChief Executive OfficerSale at price 93.91 per share.45,568
2/4/2026DANIELS JENNIFER M.OfficerSale at price 94.34 per share.22,000
11/21/2025MASSEY SALLYOfficerSale at price 80.89 per share.1,237

Frequently Asked Questions

Q. What is the current target price and upside for CL?

A. The current target price for Colgate-Palmolive Company is $97.65, which implies a 6.6% upside from the current price of $91.63. This is based on the consensus of 20 Wall Street analysts.

Q. What is the current analyst recommendation for CL?

A. Currently, there are 6 Strong Buy, 7 Buy, 7 Hold, 0 Sell, and 1 Strong Sell ratings. The overall consensus is BUY.

Q. Are insiders buying CL stock recently?

A. Over the past 6 months, there have been 0 insider buys and 10 insider sells. Insider selling is more prominent recently.

Other Promising Stocks in Consumer Staples

Data provided by Yahoo Finance. This information is for informational purposes only and does not constitute investment advice. We bear no legal responsibility for any investment decisions made based on this data.

Read full disclaimer